SCHEMBL19992033

SCHEMBL19992033

FC(F)(F)CCn1cccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
DAO P14920 1/20 0.38
FDPS P14324 1/20 0.36
TSHR P16473 1/20 0.34
GAA P10253 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
THRB P10828 1/20 0.31
IDO1 P14902 1/20 0.31
HTT P42858 2/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
KDM4E B2RXH2 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
KDM5A P29375 1/20 0.30
KDM2B Q8NHM5 1/20 0.30
KDM4C Q9H3R0 1/20 0.30
KDM5B Q9UGL1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16815831 0.88 DAO (0.39) LMNAPOLBDAOFDPSTSHR
SCHEMBL28667189 0.83 LMNA (0.37) LMNAPOLBDAOFDPSTSHR
SCHEMBL855608 0.78 DAO (0.38) LMNAPOLBDAOFDPSTSHR
SCHEMBL5713341 0.78 DAO (0.50) LMNAPOLBDAOFDPSTSHR
SCHEMBL1304909 0.77 FDPS (0.38) LMNAPOLBDAOFDPSTSHR
SCHEMBL13715227 0.75 DAO (0.36) LMNAPOLBDAOFDPSTSHR
SCHEMBL18780940 0.75 DAO (0.36) LMNAPOLBDAOFDPSTSHR
SCHEMBL21996409 0.75 FDPS (0.38) LMNAPOLBDAOFDPSTSHR
SCHEMBL28093550 0.75 LMNA (0.37) LMNAPOLBDAOFDPSMEN1
SCHEMBL12181347 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555098-A1 MESOIONIC IMIDAZOPYRIDINES FOR USE AS INSECTICIDES Bayer Aktiengesellschaft (DE) 2019-10-23 EP disclosed
EP-2892899-B1 IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2018-03-21 EP disclosed